Bayer's 2026 Balancing Act: Pipeline Promise Versus Cash Crunch

Bayer's pharma revival with Kerendia and new leadership faces a severe cash flow squeeze from €5B in glyphosate payments, with a pivotal Supreme Court ruling ahead.

The coming months will define Bayer's trajectory, as promising pharmaceutical growth collides with a severe cash flow squeeze. While new drug approvals and a strategic US leadership change signal a forward path, the shadow of multibillion-euro glyphosate settlements threatens to derail the company's financial stability in the near term.

Central to the pharmaceutical revival is the heart and kidney drug Kerendia. Its sales surged by almost 93% in the fourth quarter of 2025, reaching €264 million and contributing to an annual revenue of €829 million. The European Commission recently expanded its approved use to include a form of heart failure, opening up a potential new patient pool of 7.5 million people across Europe. Management has set a long-term peak sales target of €3 billion annually for the drug.

This push is part of a broader strategic overhaul. Effective May 1, 2026, Nelson Ambrogio will take the helm of Bayer U.S. Pharmaceuticals, tasked with accelerating growth in the company's most critical market. The move is designed to offset upcoming patent expirations for blockbusters Xarelto and Eylea. Beyond Kerendia, Bayer is banking on a new generation of products including the prostate cancer treatment Nubeqa, the non-hormonal menopause therapy Lynkuet, and the stroke prevention drug Asundexian.

At a recent media event, the company outlined ambitious financial targets for its pharmaceuticals division: a return to mid-single-digit sales growth by 2027 and an EBITDA margin of approximately 30% by 2030. To fuel this pipeline, Bayer plans to boost research productivity by 40% by the end of the decade through proprietary AI tools and external partnerships.

However, these operational ambitions are starkly contrasted by the group's deteriorating financial health. Bayer's free cash flow already fell by around 33% in 2025 to €2.1 billion. For 2026, management anticipates a significantly negative free cash flow, driven largely by an estimated €5 billion in payments related to glyphosate litigation. This puts immense pressure on a balance sheet carrying a net debt of nearly €30 billion.

All eyes are now on the US Supreme Court. Hearings concerning the proposed Missouri settlement, intended to resolve the bulk of pending and future lawsuits, begin on April 27, with a ruling expected in the second half of June. The outcome could be decisive for Bayer's financial flexibility. The Annual General Meeting on April 24, where a dividend of €0.11 per share is proposed, falls squarely in this period of high uncertainty.

Amid the legal turmoil, the company has confirmed its 2026 EBITDA forecast of €9.6 to €10.1 billion. It has also noted that current US-EU trade frameworks cap potential tariffs on European pharma products at 15%, a level already factored into its planning. The next significant milestone arrives in May with the Q1 2026 results, which will include Bayer's first official commentary on the ongoing glyphosate proceedings—a statement investors have awaited for years.

The narrative for Bayer in 2026 is one of stark duality. A reinvigorated pharmaceuticals business is charting a clear course for growth, while the corporate entity navigates a precarious cash flow cliff. The company's near-term fate may well be determined not in its research labs, but in a courtroom in Washington.